CY1116374T1 - Θεραπεια για τη λοιμωξη με τον ιο της ηπατιτιδας β μονο ή σε συνδυασμο με τον ιο της ηπατιτιδας δελτα και σχετιζομενες ασθενειες του ηπατος - Google Patents

Θεραπεια για τη λοιμωξη με τον ιο της ηπατιτιδας β μονο ή σε συνδυασμο με τον ιο της ηπατιτιδας δελτα και σχετιζομενες ασθενειες του ηπατος

Info

Publication number
CY1116374T1
CY1116374T1 CY20151100380T CY151100380T CY1116374T1 CY 1116374 T1 CY1116374 T1 CY 1116374T1 CY 20151100380 T CY20151100380 T CY 20151100380T CY 151100380 T CY151100380 T CY 151100380T CY 1116374 T1 CY1116374 T1 CY 1116374T1
Authority
CY
Cyprus
Prior art keywords
treatment
combination
usitis
usita
infection
Prior art date
Application number
CY20151100380T
Other languages
English (en)
Inventor
Nikolai Naoumov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1116374T1 publication Critical patent/CY1116374T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση αφορά την χρήση αναστολέων κυκλοφιλίνης (όπως αλισποριβίρη ή DEB025) κατά την θεραπεία λοιμώξεων με τον ιό της ηπατίτιδας Β και ηπατίτιδας D, προαιρετικά σε συνδυασμό με ιντερφερόνη ή τελβιβουδίνη, λαμιβουδίνη, εμτρισιταβίνη, εντεκαβίρη, αδεφοβίρη ή τενοφοβίρη.
CY20151100380T 2011-04-01 2015-04-24 Θεραπεια για τη λοιμωξη με τον ιο της ηπατιτιδας β μονο ή σε συνδυασμο με τον ιο της ηπατιτιδας δελτα και σχετιζομενες ασθενειες του ηπατος CY1116374T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470666P 2011-04-01 2011-04-01
EP12713680.2A EP2694087B1 (en) 2011-04-01 2012-03-30 Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases

Publications (1)

Publication Number Publication Date
CY1116374T1 true CY1116374T1 (el) 2017-02-08

Family

ID=45952512

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100380T CY1116374T1 (el) 2011-04-01 2015-04-24 Θεραπεια για τη λοιμωξη με τον ιο της ηπατιτιδας β μονο ή σε συνδυασμο με τον ιο της ηπατιτιδας δελτα και σχετιζομενες ασθενειες του ηπατος

Country Status (22)

Country Link
US (3) US20140011736A1 (el)
EP (2) EP2694087B1 (el)
JP (1) JP2014509630A (el)
KR (1) KR20140010097A (el)
CN (1) CN103458913A (el)
AU (2) AU2012237295A1 (el)
BR (1) BR112013024809A2 (el)
CA (1) CA2831675A1 (el)
CY (1) CY1116374T1 (el)
DK (1) DK2694087T3 (el)
ES (1) ES2533213T3 (el)
HK (1) HK1193571A1 (el)
HR (1) HRP20150430T1 (el)
MX (1) MX2013011411A (el)
PL (1) PL2694087T3 (el)
PT (1) PT2694087E (el)
RS (1) RS53911B1 (el)
RU (1) RU2013148779A (el)
SI (1) SI2694087T1 (el)
SM (1) SMT201500132B (el)
TW (1) TW201247216A (el)
WO (1) WO2012131061A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208746A1 (en) * 2011-01-12 2012-08-16 Scynexis Inc. Genetic markers associated with response to cyclophilin-binding compounds
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN107530338B (zh) 2015-04-21 2020-12-01 艾格尔峰生物制药有限公司 包含洛那法尼和利托那韦的药物组合物
RU2662161C1 (ru) * 2017-08-11 2018-07-24 Васильевич Иващенко Александр Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита
JP2021534218A (ja) * 2018-08-23 2021-12-09 アイガー・バイオファーマシューティカルズ・インコーポレイテッドEiger Biopharmaceuticals, Inc. インターフェロンラムダでのデルタ肝炎ウイルス感染処置
US20220313690A1 (en) * 2019-07-18 2022-10-06 Enyo Pharma Synergistic effect of eyp001 and ifn for the treatment of hbv infection
CN114945361A (zh) * 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
CN113662945A (zh) * 2020-05-15 2021-11-19 福建广生堂药业股份有限公司 用于治疗乙型肝炎的组合

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
EP0251575B2 (en) * 1986-06-17 2002-11-13 Chiron Corporation Hepatitis delta diagnostics and vaccines, their preparation and use
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ES2174915T3 (es) 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DK1793844T3 (da) * 2004-10-01 2011-03-21 Debiopharm Sa Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
AU2005322242B2 (en) 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment

Also Published As

Publication number Publication date
BR112013024809A2 (pt) 2016-09-06
CN103458913A (zh) 2013-12-18
HK1193571A1 (en) 2014-09-26
EP3006037A1 (en) 2016-04-13
RU2013148779A (ru) 2015-05-10
US20160101146A1 (en) 2016-04-14
EP2694087B1 (en) 2015-01-28
ES2533213T3 (es) 2015-04-08
AU2016201888A1 (en) 2016-04-21
US20140011736A1 (en) 2014-01-09
MX2013011411A (es) 2014-04-14
HRP20150430T1 (hr) 2015-05-22
PT2694087E (pt) 2015-04-09
WO2012131061A1 (en) 2012-10-04
RS53911B1 (en) 2015-08-31
PL2694087T3 (pl) 2015-06-30
SI2694087T1 (sl) 2015-05-29
AU2012237295A1 (en) 2013-09-19
KR20140010097A (ko) 2014-01-23
SMT201500132B (it) 2015-07-09
EP2694087A1 (en) 2014-02-12
US20150023917A1 (en) 2015-01-22
DK2694087T3 (en) 2015-04-13
JP2014509630A (ja) 2014-04-21
TW201247216A (en) 2012-12-01
CA2831675A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
CY1116374T1 (el) Θεραπεια για τη λοιμωξη με τον ιο της ηπατιτιδας β μονο ή σε συνδυασμο με τον ιο της ηπατιτιδας δελτα και σχετιζομενες ασθενειες του ηπατος
CY1121452T1 (el) Παραγωγα πουρινης για τη θεραπευτικη αντιμετωπιση ιικων λοιμωξεων
CY1124327T1 (el) Τροποποιηση της εκφρασης του ιου ηπατιτιδας β (hbv)
CY1123570T1 (el) Τροποποιητες πυρηνικης πρωτεϊνης ηπατιτιδας β
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
CY1117971T1 (el) Μακροκυκλικες πουρινες για την θεραπευτικη αντιμετωπιση ιικων λοιμωξεων
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
CR20130424A (es) Terapéuticos a base de levadura para infección de la hepatitis b crónica
EA201690979A1 (ru) Производные азепана и способы лечения инфекций гепатита в
PH12015501276A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
UY34570A (es) Combinaciones de compuestos inhibidores de la proteína ns5a en el virus de hepatitis c
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CY1118774T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
EA201491223A1 (ru) Противовирусные агенты против гепатита в
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
EA201270616A1 (ru) Ингибиторы вируса гепатита с
EA201490208A1 (ru) Тенофовир алафенамида гемифумарат
BR112014033080A2 (pt) inibidores do vírus da hepatite c
EA201400528A1 (ru) Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
CY1121334T1 (el) Αναστολεας κινασης aurora a
CY1124220T1 (el) Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα με ιντερφερονη λαμδα